Lonza Group Ltd News Release - Annual General Meeting 2013 Dienstag, 09. April 2013 - 17:32

Shareholders Approve All Proposed Agenda Items of Lonza Board of Directors

Basel, Switzerland, 9 April 2013 – Today’s Annual General Meeting of Lonza Group Ltd led by the Chairman of the Board of Directors, Rolf Soiron, was attended by 382 shareholders. They represented 44,13 % of the share capital.

The Board members standing for re-election (Patrick Aebischer, Jean-Daniel Gerber, Margot Scheltema, Rolf Soiron and Peter Wilden) were all elected for a further term in office of one year. The proposed new members Werner J. Bauer, Thomas Ebeling and Antonio Trius were newly elected to the Board of Directors. Sir Richard Sykes, Gerhard Mayr and Jörg Reinhardt did not stand for re-election as previously announced. The shareholders supported all motions proposed by the Board of Directors with great majority. A dividend of CHF 2.15 per share will be paid out as from 16 April 2013.

The shareholders also approved the renewal of the authorized share capital in a maximum amount of CHF 5 million for a period of two years until 9 April 2015.

For further information, please see the short form minutes of the Lonza Annual General Meeting under the following link (select “Annual General Meeting”).

About Lonza

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final product manufacture. It is the global leader in the production and support of chemical and biological active pharmaceutical ingredients. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is also the world leader in microbial control providing innovative, chemistry-based and related solutions to destroy or to selectively inhibit the growth of harmful microorganisms. Its activities encompass the areas of water treatment, personal care, health and hygiene, industrial preservation, materials protection, and wood treatment. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition and agro markets. Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange and secondary listed on the Singapore Exchange Securities Trading Limited (“SGX-ST”). In 2012, the company had sales of CHF 3.925 billion. Further information can be found at www.lonza.com.

Further Information